Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves new combination product to treat chronic hepatitis C infection

The US Food and Drug Administration (FDA) has approved a new combination product to treat patients chronically infected with the hepatitis C virus (HCV).

Merck & Co’s Zepatier (elbasvir and grazoprevir) can be taken with or without ribavirin and has been approved to treat adult patients with genotypes 1 and 4 of the disease. The drug was designated as a ‘breakthrough therapy’ by the FDA because evidence suggested that it may offer a substantial improvement over available treatment for a serious condition.

The safety and efficacy of Zepatier was evaluated in clinical trials involving 1,373 patients with chronic HCV genotype 1 or 4 infections, with and without cirrhosis. The participants received the treatment with or without ribavirin once daily for 12 or 16 weeks.

The overall sustained virologic response (SVR) rates ranged from 94% to 97% in genotype 1-infected subjects and from 97% to 100% in genotype 4-infected subjects. The most common side effects of Zepatier without ribavirin were fatigue, headache and nausea. The most common side effects of Zepatier taken with ribavirin were anaemia and headache.

Because of a risk of significantly raised liver enzymes in 1% of patients treated with Zepatier, blood tests should be performed before starting therapy and patients should be monitored during treatment. Zepatier should not be given to patients with moderate or severe liver impairment.

The FDA advises clinicians to screen genotype 1a-infected patients for certain viral genetic variations to determine the optimum dosage regimen and duration, which are listed in the product information.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200620

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US Food and Drug Administration (FDA), pictured, has approved a new combination product to treat patients chronically infected with the hepatitis C virus (HCV)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.